We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+3.34%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$17.4B
AUM Growth
+$71.8M
Cap. Flow
-$218M
Cap. Flow %
-1.26%
Top 10 Hldgs %
90.2%
Holding
115
New
7
Increased
18
Reduced
11
Closed
14

Top Buys

Rank Stock Value
1
ROIV icon
Roivant Sciences
ROIV
+$27.7M
2
ABCL icon
AbCellera Biologics
ABCL
+$26.2M
3
RARE icon
Ultragenyx Pharmaceutical
RARE
+$23.1M
4
DNLI icon
Denali Therapeutics
DNLI
+$21.2M
5
GLUE icon
Monte Rosa Therapeutics
GLUE
+$12.2M

Top Sells

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$63.1M
2
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$55.9M
3
DICE
DICE Therapeutics, Inc. Common Stock
DICE
+$48.1M
4
IMGN
Immunogen Inc
IMGN
+$28.7M
5
ANAB icon
AnaptysBio
ANAB
+$12.8M

Sector Composition

Rank Sector Weight
1 Healthcare 99.2%
2 Financials 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NRIX icon
26
Nurix Therapeutics
NRIX
$2.47B
$30.5M 0.18%
3,882,125
– –
BMEA icon
27
Biomea Fusion
BMEA
$89.7M
$29M 0.17%
2,108,949
– –
IDYA icon
28
IDEAYA Biosciences
IDYA
$3.47B
$28.7M 0.17%
1,062,123
– –
CERS icon
29
Cerus
CERS
$581M
$27.9M 0.16%
17,239,501
+1,171,943
+7% +$2.44M
JBIO
30
Jade Biosciences
JBIO
$1.19B
$26.6M 0.15%
56,099
– –
IGMS
31
DELISTED
IGM Biosciences
IGMS
$26.4M 0.15%
3,157,764
+554
+0% +$4.7K
XENE icon
32
Xenon Pharmaceuticals
XENE
$6.2B
$25.7M 0.15%
751,639
– –
CABA icon
33
Cabaletta Bio
CABA
$435M
$24.3M 0.14%
1,594,000
– –
GLUE icon
34
Monte Rosa Therapeutics
GLUE
$1.85B
$23.5M 0.14%
4,916,095
+1,892,144
+63% +$12.2M
DBVT
35
DBV Technologies
DBVT
$797M
$19.9M 0.11%
1,461,426
– –
KRYS icon
36
Krystal Biotech
KRYS
$10.7B
$19.7M 0.11%
169,934
– –
VERV
37
DELISTED
Verve Therapeutics
VERV
$18.8M 0.11%
1,416,530
– –
BCYC
38
Bicycle Therapeutics
BCYC
$271M
$17M 0.1%
843,814
– –
IMVT icon
39
Immunovant
IMVT
$8B
$16.3M 0.09%
+425,009
New +$9.61M
COGT icon
40
Cogent Biosciences
COGT
$6.83B
$12.6M 0.07%
1,292,966
+313,366
+32% +$3.72M
DAWN
41
DELISTED
Day One Biopharmaceuticals
DAWN
$12.3M 0.07%
1,000,000
– –
PRME icon
42
Prime Medicine
PRME
$553M
$9.81M 0.06%
1,028,466
– –
TSVT
43
DELISTED
2seventy bio
TSVT
$9.79M 0.06%
2,497,526
– –
RLAY icon
44
Relay Therapeutics
RLAY
$4.07B
$9.76M 0.06%
1,160,117
– –
PACB icon
45
Pacific Biosciences
PACB
$441M
$9.42M 0.05%
1,127,782
– –
INSM icon
46
Insmed
INSM
$22.5B
$8.66M 0.05%
343,000
– –
ADAP
47
DELISTED
Adaptimmune Therapeutics
ADAP
$8.56M 0.05%
10,969,282
– –
TNGX icon
48
Tango Therapeutics
TNGX
$4.24B
$8.45M 0.05%
750,000
– –
HRTX icon
49
Heron Therapeutics
HRTX
$93.3M
$8.38M 0.05%
8,131,678
– –
ARVN icon
50
Arvinas
ARVN
$532M
$8.12M 0.05%
+413,481
New +$10.1M
1
2
3 4 5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q3 2023 Portfolio in Review

As of Q3 2023, Baker Bros. Advisors held 115 positions worth $17.4B, up 0.42% from $17.3B the previous quarter. Its ten largest holdings account for 90% of the portfolio.

Baker Bros. Advisors's Q3 2023 filing shows 7 new, 18 increased, 11 reduced and 14 closed positions. Its largest new stake was Morphic Holding, Inc. Common Stock: 215,800 shares worth $4.94M. The largest sale was argenx, an estimated $63.1M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Financials.

  • Baker Bros. Advisors's largest Q3 2023 buy was Morphic Holding, Inc. Common Stock: 215,800 shares worth $4.94M.
  • Baker Bros. Advisors added most to Roivant Sciences in Q3 2023, an estimated $27.7M increase.
  • Baker Bros. Advisors's biggest Q3 2023 reduction was argenx, cutting an estimated $63.1M.
  • Baker Bros. Advisors fully exited Chinook Therapeutics, Inc. Common Stock in Q3 2023, selling an estimated $55.9M.
  • Baker Bros. Advisors's ten largest holdings make up 90% of its $17.4B portfolio in Q3 2023.
  • Baker Bros. Advisors opened 7 new positions and closed 14 in Q3 2023.
  • Baker Bros. Advisors's portfolio value rose 0.42% quarter-over-quarter to $17.4B.

Based on Baker Bros. Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.